Association between Forced Expiratory Volume in 1 second /Forced Vital Capacity ratio and Main Pulmonary Artery /Ascending Aorta ratio in Chronic Obstructive Pulmonary Disease Patients – A Hospital based Observational Study
Keywords:
COPD, FEV1/FVC, LDCT, MPA/AA, Observational studyAbstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a condition marked by persistent airflow limitation with an enhanced inflammatory response in airways and alveoli. Key risk factors for COPD include smoking, exposure to environmental pollutants, and genetic predisposition. Low dose computed tomography (LDCT) chest offers valuable insights into structural and vascular abnormalities in COPD, contributing to better understanding of its phenotypes, severity and disease outcomes.
Objective: This study aims to evaluate the correlation between disease severity (FEV1/FVC) and MPA/AA ratio in LDCT chest.
Methods: This observational study included a total of 112 spirometry confirmed COPD patients. LDCT chest was performed to assess parenchymal abnormalities and vascular involvement. Statistical analyses were conducted to determine the significant association between disease severity (FEV1/FVC) ratio, MPA/AA ratio and frequency of exacerbations over one year.
Results: Patients with very severe and severe COPD disease exhibited elevated MPA/AA ratio and reduced FEV1/FVC ratio, with a significant negative correlation between FEV1/FVC and MPA/AA (r = -0.533, p = 0.001). A strong association was observed between increased MPA/AA ratio (>0.9) and higher risk of exacerbations (p < 0.001, OR = 2.42, 95% CI: 4.811–15.365). The most common parenchymal abnormality detected on LDCT chest was mosaic attenuation, observed in 38 patients.
Conclusion: This study focuses the utility of LDCT chest in COPD patients. The strong correlation between FEV1/FVC ratio, MPA/AA ratio and exacerbation frequency emphasises the disease severity in COPD patients, thus facilitating targeted interventions to improve disease condition.
Downloads
Metrics
References
Barberà JA, Blanco I. Chronic obstructive pulmonary disease (COPD). In: Pulmonary Circulation 2016;497-508.
Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023;79:516-37.
Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 2022;10:497-511.
Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J 2018;52:1801261.
Stolz D, Barandun J, Borer H, Bridevaux PO, Brun P, Brutsche M, et al. Diagnosis, prevention and treatment of stable COPD and acute exacerbations of COPD: the Swiss recommendations 2018. Respiration 2018;96:382-98.
Ye X, Wang Y, Zou Y, Tu J, Tang W, Yu R, et al. Associations of socioeconomic status with infectious diseases mediated by lifestyle, environmental pollution and chronic comorbidities: a comprehensive evaluation based on UK Biobank. Infect Dis Poverty 2023;12:1-23.
Yip R, Jirapatnakul A, Hu M, Chen X, Han D, Ma T, et al. Added benefits of early detection of other diseases on low-dose CT screening. Transl Lung Cancer Res 2021;10:1141-55.
Sun H, Gao F, Li N, Liu C. An evaluation of the feasibility of assessment of volume perfusion for the whole lung by 128-slice spiral CT. Acta Radiol 2013;54:921-7.
Polosukhin VV, Gutor SS, Du RH, Richmond BW, Massion PP, Wu P, et al. Small airway determinants of airflow limitation in chronic obstructive pulmonary disease. Thorax 2021;76:1079-88.
Usmani OS, Dhand R, Lavorini F, Price D. Why we should target small airways disease in our management of chronic obstructive pulmonary disease. Mayo Clin Proc 2021;96:822-32.
Usmani OS, Han MK, Kaminsky DA, Hogg J, Hjoberg J, Patel N, et al. Seven pillars of small airways disease in asthma and COPD: supporting opportunities for novel therapies. Chest 2021;160:114-34.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
